文献速递外周动脉疾病

肾移植受者外周血管介入术后对比剂相关急性肾损伤分析

Postcontrast Acute Kidney Injury after Peripheral Vascular Interventions in Kidney Transplant Recipients.
PubMed 文献 · Ann Vasc Surg · 2020-05-16

基于血管质量倡议(VQI)2010–2018年外周血管介入(PVI)数据,纳入58,014例次手术(其中肾移植受者641例次,占1%),比较肾移植受者与非移植患者的围术期结局。肾移植受者对比剂相关急性肾损伤(PC-AKI)发生率为2.8%,非移植患者为0.9%;倾向性评分匹配后两组PC-AKI风险相似。华法林使用(OR=4.7)和移植肾功能差(OR=4.0)与肾移植受者PC-AKI风险升高显著相关。

要点

  • 肾移植受者PVI术后PC-AKI发生率为2.8%,高于非移植患者的0.9%。
  • 倾向性评分匹配后,肾移植受者与非移植患者PC-AKI风险相似。
  • 华法林使用和移植肾功能差与肾移植受者PC-AKI风险升高相关。

核心结论

  • 肾移植受者PVI术后PC-AKI发生率高于总体PVI人群,但与非移植倾向性匹配患者相比未见升高。
  • 肾移植受者行PVI治疗外周动脉疾病安全,围术期及长期生存可接受。

研究设计与样本

  • 回顾性队列研究,数据来源于血管质量倡议(VQI)外周血管介入文件(2010–2018年)。
  • 共分析58,014例次手术,其中肾移植受者641例次(1%);排除透析患者。
  • 比较肾移植受者与非移植患者特征,采用倾向性评分匹配控制基线差异,多因素logistic回归分析PC-AKI危险因素,Kaplan-Meier分析比较生存。

主要发现

  • 肾移植受者PC-AKI发生率为2.8%,非移植患者为0.9%。
  • 肾移植受者中,基线华法林使用(OR=4.7)和移植肾功能差(OR=4.0)与PC-AKI风险升高显著相关。
  • 与非移植匹配组相比,肾移植受者PC-AKI风险相似,术后心肌梗死风险更高(OR=4.3),但院内死亡率更低(OR=0.22)。

关键数值与推荐

  • PC-AKI定义为VQI标准:肌酐升高≥0.5 mg/dL或需要新透析。
  • 肾移植受者PC-AKI发生率2.8%,非移植患者0.9%。
  • 华法林使用OR=4.7,移植肾功能差OR=4.0,均为肾移植受者PC-AKI的危险因素。
  • 与非移植匹配组比较,术后心肌梗死OR=4.3,院内死亡OR=0.22。

临床怎么用

  • 肾移植受者行PVI时应评估PC-AKI风险,尤其关注华法林使用和移植肾功能差的患者。
  • 肾移植受者PVI术后需警惕心肌梗死,但院内死亡风险相对较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postcontrast acute kidney injury (PC-AKI) is a feared complication of peripheral vascular interventions (PVIs), associated with increased mortality. Whether kidney transplant recipients (KTRs) are at increased risk of PC-AKI after PVI is unknown. This study analyzes the perioperative outcomes of KTR following PVI, with emphasis on the incidence and risk factors for PC-AKI. METHODS: The Vascular Quality Initiative files for PVI (2010-2018) were reviewed. Patients on dialysis were excluded. PC-AKI was defined by Vascular Quality Initiative as creatinine increase ≥0.5 mg/dL or new dialysis requirement. Characteristics of KTR and patients without kidney transplant were compared, and propensity score matching used to control for differences in baseline features. Multivariable logistic regression was used to define risk factors for PC-AKI, and survival was compared using Kaplan-Meier analysis. RESULTS: A total of 58,014 procedures were analyzed, including 641 (1%) procedures for KTR. The incidence of PC-AKI in KTR was 2.8% compared with 0.9% in patients without kidney transplants. Baseline warfarin use (odds ratio [OR] = 4.7) and poor allograft function (OR = 4.0) were significantly associated with increased risk for PC-AKI in KTR. Compared with a matched group of patients without kidney transplant, KTR had similar risk of PC-AKI and were more likely to develop postop myocardial infarction (OR = 4.3) but had lower in-hospital mortality (OR = 0.22). CONCLUSIONS: The incidence of PC-AKI in KTR is higher than the overall population undergoing PVI but is not elevated compared with propensity-matched patients without kidney transplant. PVI for peripheral artery disease in KTR is safe and associated with acceptable perioperative and long-term survival.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lee SR, Dardik A, Ochoa Chaar CI, et al. Postcontrast Acute Kidney Injury after Peripheral Vascular Interventions in Kidney Transplant Recipients. Ann Vasc Surg. 2020. PMID: 32428641. doi:10.1016/j.avsg.2020.04.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。